We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $18.9 · 10 analysts
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Stored first · Google News · Yahoo Finance (English)
Stifel cuts Fulcrum Therapeutics stock rating on drug discontinuation By Investing.com - Investing.com Nigeria
Stifel cuts Fulcrum Therapeutics stock rating on drug discontinuation By Investing.com Investing.com Nigeria
Stifel Downgrades Fulcrum Therapeutics (FULC) to Hold - StreetInsider
Stifel Downgrades Fulcrum Therapeutics (FULC) to Hold StreetInsider
FULC Stock Slumps Nearly 50% After Hours As FDA Kills Only Clinical Program Over Cancer Risk - TradingView
FULC Stock Slumps Nearly 50% After Hours As FDA Kills Only Clinical Program Over Cancer Risk TradingView
FULC Stock Slumps Nearly 50% After Hours As FDA Kills Only Clinical Program Over Cancer Risk
FULC Stock Slumps Nearly 50% After Hours As FDA Kills Only Clinical Program Over Cancer Risk - Stocktwits
FULC Stock Slumps Nearly 50% After Hours As FDA Kills Only Clinical Program Over Cancer Risk Stocktwits
Why is Fulcrum Therapeutics stock collapsing after-hours? - Investing.com
Why is Fulcrum Therapeutics stock collapsing after-hours? Investing.com
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 04. 27. | After market close (AMC) | $-0.28 | — | — | $0 | — | Scheduled |
| FY2022 Q3 | 2021. 09. 30. | Time TBD | — | $-1.71 | — | — | $7.8M | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 01. 12. | JP Morgan | — | Initiate coverage | — → Overweight | — | JP Morgan: Overweight |
| 2025. 12. 12. | Truist Securities | — | Maintain | Buy → Buy | — | Truist Securities: Buy |
Compare a firm's past rating changes and its actions on other stocks in the same sector.
As of FY2026Q1 · Source: SEC/DART + price data
Filings, earnings, and institutional changes summarized in one paragraph, with source links.
| # | Institution | Mandate | Shares | Value | Weight | Change | Position |
|---|---|---|---|---|---|---|---|
| 1 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 2,398,232 | $27.12B | 0.04% | — | New position |
| 2 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 2,074,855 | $15.91B | 0.03% | — | New position |
See new positions, full exits, and weight changes.